MyAmyloidosisTeam

Tafamidis (Vyndamax) works by stabilizing the transthyretin protein in your body, which prevents it from breaking down into smaller fragments that could form harmful amyloid deposits. This medication was the first FDA-approved drug for treating both hereditary and wild-type cardiac ATTR amyloidosis. Clinical studies have Show Full Answer

Tafamidis (Vyndamax) works by stabilizing the transthyretin protein in your body, which prevents it from breaking down into smaller fragments that could form harmful amyloid deposits. This medication was the first FDA-approved drug for treating both hereditary and wild-type cardiac ATTR amyloidosis. Clinical studies have shown that tafamidis effectively slows disease progression and reduces the risk of cardiac-related hospitalization and death in people with ATTR amyloidosis. Research demonstrates that starting treatment earlier and maintaining it longer leads to better outcomes, including improved neurological function and quality of life scores.

 AI-generated responses are not a substitute for medical advice. These services are not intended to diagnose, treat, or cure any condition or disease. Always ask your doctor about specific health concerns.

8 Amyloidosis Treatments and Their Side Effects

Is Cardiac Amyloidosis Curable?